Merck & Co., Inc. Reports Q3 2026 Financial Results
Merck & Co., Inc. announced its financial results for the third quarter of 2026, reporting a non-GAAP loss per share of $0.13 and updating its full-year 2026 revenue and EPS guidance.
Stocks · News reference
Jefferies & Co. Adjusts Merck Price Target to $177 from $176
Jefferies & Co. has updated its price target for Merck & Co., Inc. (NYSE: MRK), raising it to $177 from the previous target of $176.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.
HKSTP Partners with Merck to Advance Innovation and Technology
The Hong Kong Science and Technology Parks Corporation (HKSTP) has entered into a partnership with Merck to foster innovation and technology development in the region.